Expert Review of Hematology最新文献_第9页

NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy. 非甾体抗炎药/COXIBS治疗血友病关节病继发的肌肉骨骼疼痛。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1080/17474086.2024.2438237

E Carlos Rodriguez-Merchan, Hortensia De la Corte-Rodriguez

{"title":"NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy.","authors":"E Carlos Rodriguez-Merchan, Hortensia De la Corte-Rodriguez","doi":"10.1080/17474086.2024.2438237","DOIUrl":"10.1080/17474086.2024.2438237","url":null,"abstract":"Introduction: Cyclooxygenase-2 (COX-2) inhibitors (COXIBS) are considered a suitable option for the treatment of hemophilic arthropathy.Areas covered: The role of traditional non-steroidal anti-inflammatory drugs; (NSAIDS) and COXIBS in people with hemophilia (PWH) and in the non-hemophiliac population has been reviewed in order to know which of them is more advisable in PWH and whether they should be used as the first or second therapeutic step for the treatment of musculoskeletal pain (since there is a discrepancy between what is advised by the WFH and the WHO).Expert opinion: For the treatment of chronic musculoskeletal pain related to hemophilic arthropathy, it is reasonable to use as a first step a combination of oral paracetamol (650 mg per every 6 h) or metamizole (575 mg per every 6 h), one of the COXIBS (e.g. celecoxib 200 mg per once a day) and a proton pump inhibitor (e.g. omeprazole 20 mg per once a day). The possible side effects of COXIBS should never be forgotten. For the treatment of hemophilic arthropathy pain, the risk/benefit ratio of COXIBS should be carefully assessed on an individual basis, although they are more advisable than traditional NSAIDS.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"33-38"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel approaches for preventing COVID-19 infection in immunocompromised patients with hematologic malignancies. 预防血液系统恶性肿瘤免疫功能低下患者COVID-19感染的新方法

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-03 DOI: 10.1080/17474086.2024.2436973

Shmuel Shoham, Daniele Focosi, Massimo Franchini, Alaa Atamna

{"title":"Novel approaches for preventing COVID-19 infection in immunocompromised patients with hematologic malignancies.","authors":"Shmuel Shoham, Daniele Focosi, Massimo Franchini, Alaa Atamna","doi":"10.1080/17474086.2024.2436973","DOIUrl":"10.1080/17474086.2024.2436973","url":null,"abstract":"Introduction: COVID-19 is a continuing challenge for immunocompromised patients with hematological malignancies. Such patients are at increased risk for complications, including hospitalization, respiratory failure, delayed anti-cancer therapies, and even death. In addition to non-pharmacologic interventions, the main strategies for prevention in such patients are vaccination and pre-exposure prophylaxis.Areas covered: In this narrative review, which relied on a review of the PubMed and bioRxiv databases (starting 1 November 2019), we summarize the epidemiology of COVID-19 and vaccine responses in patients with hematological malignancies and the use of antiviral agents as prophylaxis. A limitation to vaccination is suboptimal immune responses in immunocompromised patients, particularly those with abnormalities in lymphocyte count and function. A limitation to prophylaxis, which has only been proven effective for antiviral monoclonal antibodies (mAbs), is the emergence of resistant strains in the general population.Expert opinion: For immunocompromised patients with hematological malignancies, we recommend vaccinations as guided by evolving US Centers for Disease Control and Prevention (CDC) recommendations, consideration of pre-exposure prophylaxis with antiviral mAbs, providing that they are effective against circulating viral strains, and rapid diagnostic testing linked to early therapy for the prevention of severe complications of COVID-19 in those who have broken through the prevention strategies.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"39-46"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radioimmunotherapy of acute myeloid leukemia: a critical assessment of its prospects and limitations. 急性髓性白血病的放射免疫治疗：对其前景和局限性的关键评估。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-01-10 DOI: 10.1080/17474086.2025.2449863

Donald Bunjes

引用次数: 0

Problems faced by people with hemophilia aged 18-35 years in social life: a qualitative study. 18-35岁血友病患者在社会生活中面临的问题：一项定性研究。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-02-21 DOI: 10.1080/17474086.2025.2468386

Selin Davun, Zeynep Meva Altaş, Mahmut Batman, Melda Karavuş, Mehmet Mert Baykara, Beyza Doğan, Nabila Salehin, Sarp Kayauman, Ahmet Celal Demirel, Seyhan Hıdıroğlu

{"title":"Problems faced by people with hemophilia aged 18-35 years in social life: a qualitative study.","authors":"Selin Davun, Zeynep Meva Altaş, Mahmut Batman, Melda Karavuş, Mehmet Mert Baykara, Beyza Doğan, Nabila Salehin, Sarp Kayauman, Ahmet Celal Demirel, Seyhan Hıdıroğlu","doi":"10.1080/17474086.2025.2468386","DOIUrl":"10.1080/17474086.2025.2468386","url":null,"abstract":"Background: The aim of this qualitative study is to determine and evaluate the problems faced by people with hemophilia aged 18-35 years in their social lives.Research design and methods: In this qualitative type research, 13 individuals aged 18-35 years with hemophilia were reached with snowball sampling and online interviews with them. Participants were asked about their sociodemographic characteristics and the problems they encountered in various fields related to hemophilia using a semi-structured question guide with open-ended questions. Thematic content analysis was carried out.Results: Most participants were diagnosed with hemophilia in early childhood and have maintained knowledge of the condition since then. Hemophilia-related complications often resulted in significant educational delays, with two participants unable to complete formal schooling. Experiences of stigmatization in school were commonly reported. Some families faced migration or job changes due to the financial burden of hemophilia. While the majority viewed current healthcare services in Türkiye as sufficient, access issues in rural areas were noted. Nearly all participants belonged to a hemophilia-related non-governmental organization, which they felt had greatly enhanced their quality of life.Conclusions: To improve the social well-being of people with hemophilia, awareness campaigns to reduce stigma and foster a more supportive social environment are needed.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"249-256"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia. 在选择慢性淋巴细胞白血病一线治疗的指南和实际挑战之间的差距。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-02-20 DOI: 10.1080/17474086.2025.2469719

Stefano Molica

{"title":"Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia.","authors":"Stefano Molica","doi":"10.1080/17474086.2025.2469719","DOIUrl":"10.1080/17474086.2025.2469719","url":null,"abstract":"Introduction: Chronic lymphocytic leukemia (CLL) management has shifted from chemotherapy to targeted therapies like BTK and BCL-2 inhibitors, significantly improving patients' survival and quality of life. Current treatment guidelines often fail to fully address the real-world challenges of patient preferences, comorbidities, and logistical constraints. Consequently, a more personalized approach is essential to enhance decision-making and optimize treatment outcomes.Areas covered: This report delves into the challenges associated with frontline CLL therapy, emphasizing BTK inhibitors and venetoclax-based regimens. It examines patient stratification based on genetic markers, such as TP53 mutations and/or del(17p), the use of geriatric assessments for older patients, and the influence of comorbidities like cardiovascular disease and renal dysfunction. Furthermore, it highlights the need for a practical decision-making framework that integrates patient-specific considerations and addresses the limitations of existing treatment guidelines.Expert opinion: The proposed framework emphasizes a patient-centered approach that integrates clinical, genetic, and logistical factors to guide CLL treatment decisions. By addressing real-world challenges such as patient preferences for all-oral regimens and quality-of-life considerations, this approach aims to deliver truly personalized care. Future updates to CLL treatment guidelines should prioritize models that align with the unique needs and priorities of CLL patients.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"195-200"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proximal complement inhibitors in paroxysmal nocturnal hemoglobinuria: an abundance of options in a rare disease. 阵发性夜间血红蛋白尿的近端补体抑制剂：一种罕见疾病的丰富选择。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-01-06 DOI: 10.1080/17474086.2025.2449864

Taylor S White, Justin R Arnall, Paul Christopher Parish, Jamie Tolerico, Thuy Tran, Donald C Moore

引用次数: 0

Key features of the underlying pathophysiology of Transfusion-related acute lung injury. 输血相关急性肺损伤的基本病理生理特征。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-03 DOI: 10.1080/17474086.2024.2436972

Rick Kapur

{"title":"Key features of the underlying pathophysiology of Transfusion-related acute lung injury.","authors":"Rick Kapur","doi":"10.1080/17474086.2024.2436972","DOIUrl":"10.1080/17474086.2024.2436972","url":null,"abstract":"Introduction: Transfusion-related acute lung injury (TRALI) remains a leading cause of blood transfusion associated mortality, particularly in the intensive care unit. TRALI is underrecognized, underreported and lacks specific biomarkers and clinical therapies.Areas covered: In this review, the focus will be on the key pathophysiological features of TRALI. This will include the latest insights into the critical importance of complement (in contrast to Fcγ-receptors; FcγRs) as a driver of TRALI, and the role of recipient immune cells such as neutrophils and macrophages, and also the contribution of the pulmonary endothelium.Expert opinion: Increased efforts are needed to stimulate active reporting of TRALI cases. More research into the immuno-cellular pathophysiology of TRALI is required, including the role of the pulmonary endothelium. Heterogeneity in the underlying clinical condition and the different transfusion triggers should be taken into consideration. This will aid in the search for novel biomarkers and therapeutic modalities. At the moment, the most promising potential therapeutic strategies appear to be administration of interleukin (IL)-10, inhibition of complement activation and blockade of Osteopontin (OPN). Follow-up investigations are, however, highly warranted which should pave the way for multicenter international clinical trials, in order to battle the mortality due to TRALI.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"57-64"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The past, the present and the future of immune checkpoints inhibitors in multiple myeloma. 多发性骨髓瘤免疫检查点抑制剂的过去、现在和未来。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2025-02-23 DOI: 10.1080/17474086.2025.2469720

Valeria Tomarchio, Anna Crescenzi, Mariantonietta Tafuri, Martina Verri, Monica Di Cecca, Luigi Rigacci, Ombretta Annibali

{"title":"The past, the present and the future of immune checkpoints inhibitors in multiple myeloma.","authors":"Valeria Tomarchio, Anna Crescenzi, Mariantonietta Tafuri, Martina Verri, Monica Di Cecca, Luigi Rigacci, Ombretta Annibali","doi":"10.1080/17474086.2025.2469720","DOIUrl":"10.1080/17474086.2025.2469720","url":null,"abstract":"Introduction: Myeloma genesis is a very complex mechanism in which the interaction between plasma cells and microenvironments with immune cells, cytokines and chemokines have a central role. In the last years, the improved knowledge of immune checkpoint models led to the development of new drugs (anti-PD1/PD-L1 axis or anti-TIGIT) that now have a crucial role in the treatment of many hematological malignancies.Areas covered: In this review, the current significant literature was discussed. In the past, initial trials combining immune checkpoint inhibitors (ICIs) with immunomodulatory drugs or proteasome inhibitors demonstrated suboptimal results in terms of efficacy and safety. On the other hand, recent trials based on the combination of ICIs with immunotherapies, such as CAR-T cells or bispecific antibodies, are a particularly promising area of investigation.Expert opinion: Our idea after the evaluation of scientific literature is that despite the past, ICIs may represent a promising therapeutic approach for myeloma, particularly when combined with CAR-T cells or bispecific antibodies. By targeting immune evasion mechanisms, ICIs may enhance the efficacy of these treatments and provide new hope for patients with resistant disease. Future research will be crucial to further elucidate their optimal use in myeloma and to develop personalized treatment strategies.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"201-214"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions. 促进口腔健康对出血性疾病儿童生活质量的影响：消除误解。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-12-01 Epub Date: 2024-11-27 DOI: 10.1080/17474086.2024.2432354

Nayera H K El Sherif, Mariem O M Wassel, Salwa Mostafa, Fatma R R Abd El Maged, Sally E Nathan, Dina Hamdy, Fatma S E Ebeid

{"title":"The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions.","authors":"Nayera H K El Sherif, Mariem O M Wassel, Salwa Mostafa, Fatma R R Abd El Maged, Sally E Nathan, Dina Hamdy, Fatma S E Ebeid","doi":"10.1080/17474086.2024.2432354","DOIUrl":"10.1080/17474086.2024.2432354","url":null,"abstract":"Background: Understanding the disease-specific risks and patient-related barriers of children with bleeding disorders is necessary for primary oral health promotion. Our goal was to assess the oral health status and the impact of oral health promotion among patients with bleeding disorders.Research design and methods: At baseline, 70 patients with inherited and acquired bleeding disorders had a complete intraoral examination, completed the oral health-related quality of life (OHRQoL) questionnaires, and an oral health education was given. After 6 months, the effectiveness of the oral hygiene promotion was evaluated clinically and through the OHRQoL questionnaires.Results: Our cohort included 33 patients with chronic immune thrombocytopenia (cITP), 27 hemophilia A patients, and 10 with inherited thrombasthenia. Forty patients (57.1%) had dental caries, 90.0% showed fair oral hygiene status with variable degrees of gingivitis. The baseline self-image score was significantly inferior among patients with inherited bleeding disorders, while the psychological domain for family was greatly affected among cITP patients. After 6 months, there was a significant reduction in the oral debris, the modified gingival indexes, the percentages of cases with oral bleeding, and a significantly improved mean OHRQoL total score.Conclusions: After the oral health education, the OHRQoL scores had significantly improved, and oral hygiene status were acceptable among patients with bleeding disorders.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"967-975"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions. 毛细胞白血病（HCL）和 HCL 类疾病：现状、紧急治疗方案和未来方向。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-12-01 Epub Date: 2024-11-14 DOI: 10.1080/17474086.2024.2427660

Xavier Troussard

{"title":"Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions.","authors":"Xavier Troussard","doi":"10.1080/17474086.2024.2427660","DOIUrl":"10.1080/17474086.2024.2427660","url":null,"abstract":"Introduction: Hairy cell leukemia accounts for less than 2% of leukemias. The hairy cells express CD11c, CD25, CD103, and CD123 markers. The BRAFV600E mutation was detected in 95% of HCL cases. Patients achieve high complete response rate with purine analogues with or without rituximab, but relapses are inevitable. HCL-like disorders including HCL variant, splenic diffuse red pulp lymphoma, and splenic marginal zone lymphoma are BRAFV600E negative. The CD25 expression is negative. The absence of BRAFV600E mutation in HCL variant contrasts with the presence of mitogen-activated protein kinase kinase 1 (MAP2K1) mutations in 50% of cases.Areas covered: We investigated the criteria used to distinguish HCL from HCL-like disorders. Recent discoveries in molecular biology have enabled the introduction of several new drugs in HCL patients. We explore the investigational agents: inhibitors of BRAF, MEK, and Bruton tyrosine kinase and potential future strategies we will use in the future in patients with relapsed/refractory HCL. We also discuss the clinical trials in progress.Expert opinion: The association of Cladribine (CDA) with rituximab (R) is the standard first-line treatment in fit HCL and HCL variant patients. BRAF and BTK inhibitors are options in relapsed/refractory HCL patients. The optimal treatment sequences remain to be determined.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"907-915"},"PeriodicalIF":2.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0